Meet the team
Lucy Ling, VP of Biology
Amy Spoering, Dir. of Biological Research
Aaron Peoples, Dir. of Chemistry
Dallas Hughes, President
Kim Lewis
-
President
Dr. Hughes has over 30 years of experience in preclinical research and development, microbiology, and drug discovery. His experience in natural products has resulted in the discovery and preclinical development of several novel drug candidates. Prior to joining NovoBiotic Dr. Hughes was a Sr. V.P. at Cetek Pharmaceuticals.
-
VP of Biology
Dr. Ling has extensive experience in pathogen genetics, microbiology, and screening for novel antimicrobial agents. She has led multi-disciplinary teams from assay development to lead optimization, screening both synthetic small molecules and natural products. Prior to NovoBiotic Dr. Ling was at Genome Therapeutics, Waltham, MA for over 10 years.
-
Director of Biological Research
Dr. Spoering is responsible for the development and evaluation of new methodologies and technologies at NovoBiotic Pharmaceuticals. She also supervises the fermentation facility including the production of teixobactin for research purposes. Her doctoral research investigated the molecular mechanisms of bacterial tolerance to antibiotics.
-
Director of Chemistry
Mr. Peoples joined NovoBiotic after his graduate work at the University of Wisconsin–Madison, where he studied protein folding by synthesizing small peptidic model systems. His background in advanced NMR techniques and analytical separations are vital to the drug discovery process within the company. Mr. Peoples also has an extensive background in natural product isolation and characterization.
-
Dr. Lewis is a specialist in multi-drug resistance and drug discovery. He is University Distinguished Professor of Biology and Director of Antimicrobial Discovery Center at Northeastern University. Dr. Lewis is the co-inventor of the method for growing unculturable bacteria that forms the core of NovoBiotic's intellectual property.